The Pharma Data

OCTOBER 14, 2021

Breakthrough Therapy Designation is designed to accelerate the development and review of medicines intended to treat serious or life-threatening conditions with preliminary evidence that indicates they may demonstrate a substantial improvement over available therapies that have received full FDA approval. trillion per year by 2030.

Therapies 52

Therapies Disease FDA Trials 52

The Pharma Data

FEBRUARY 24, 2022

– FDA approval marks a significant breakthrough for the approximately 3 million adults in the U.S. with more than 8 million cases expected by 2030. . – FDA approval marks a significant breakthrough for the approximately 3 million adults in the U.S. with more than 8 million cases expected by 2030.

FDA Approval 52

FDA Approval FDA Hospitals Trials 52

The Pharma Data

NOVEMBER 5, 2020

FDA accepted for priority review Libtayo ® (cemiplimab-rwlc) for both advanced non-small cell lung cancer and basal cell carcinoma. FDA approved Inmazeb for Ebola ( Zaire ebolavirus). Regeneron Pharmaceuticals, Inc. About Regeneron Pharmaceuticals, Inc. Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn).

Production 40

Production FDA Trials FDA Approval 40

Codon

MARCH 24, 2024

market with Wegovy will, by 2030, require about one million liters of production capacity. Between the technical uncertainty and the horrendous PR, pharmaceutical companies had little interest in adopting molecular farming technologies. The total global bioprocessing capacity was estimated at 17.4

Engineering 87

Engineering Vaccine Production RNA 87

The Pharma Data

JANUARY 9, 2021

This growth primarily reflects increased sales of contract development and manufacturing (CDMO) services to pharmaceutical and biotechnology innovators and government/non-government organization (NGO) customers, as well as higher product sales. In working together, we envision protecting or enhancing 1 billion lives by 2030.

Government 40

Government Vaccine Production Licensing 40

The Pharma Data

APRIL 27, 2021

Pharmaceuticals. First-quarter 2021 Pharmaceutical sales increased 3.8% District Court for the District of Delaware asserting two method of use patents (US 10,583,110 and US 10, 716,777), both of which expire in October 2030. Pharmaceuticals business operating income. to €2,638 million. At CER, BOI increased 13.3%.

Vaccine 52

Vaccine Production FDA Disease 52

The Pharma Data

SEPTEMBER 15, 2020

New indication allows this first FDA-approved biomarker-based test to be used as triage for positive cobas HPV tests run on cobas 6800/8800 Systems in primary screening or co-testing programs. The World Health Organization has set goals for countries to take action to eliminate cervical cancer by 2030.

FDA Approval 52

FDA Approval FDA Laboratories Disease 52